Jasper Therapeutics (JSPR) Payables (2019 - 2026)

Jasper Therapeutics has reported Payables for 8 years, with the latest figure at $2.8 million in Q2 2026.

• On a quarterly basis, Payables fell 65.42% year-over-year to $2.8 million in Q2 2026; TTM through Jun 2026 was $2.8 million, a 65.42% decrease from a year earlier, with the FY2025 full-year figure at $6.2 million, up 54.46% from the prior year.
• Payables was $2.8 million for Q2 2026 at Jasper Therapeutics, down from $6.2 million in the prior quarter.
• The five-year high for Payables was $9.2 million in Q3 2025, with the low at $1.5 million in Q1 2022.
• Average Payables over 5 years is $3.8 million, with a median of $3.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Payables surged 811.14% in 2022, then sank 65.42% in 2026.
• Over 5 years, Payables stood at $1.8 million in 2022, then soared by 134.67% to $4.1 million in 2023, then declined by 2.94% to $4.0 million in 2024, then soared by 54.46% to $6.2 million in 2025, then sank by 55.34% to $2.8 million in 2026.
• The last three Payables figures came in at $2.8 million (Q2 2026), $6.2 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.